MedPath

Saphenous Nerve Block Versus Platelet Rich Plasma for Chronic Knee Osteoarthritis

Not Applicable
Completed
Conditions
Chronic Knee Joint Osteoarthritis
Interventions
Other: Saphenous nerve block group
Other: Platelet rich plasma group
Registration Number
NCT03326544
Lead Sponsor
Mansoura University
Brief Summary

Knee osteoarthritis, as a progressive disease is one of the most common causes of pain, motor disorder and disability in the elderly. By increasing age, the cartilage is eroded and endures degenerative changes due to physiological and biomechanical changes as well as metabolic effects and trauma . Non-surgical interventions for pain control of knee osteoarthritis include weight loss, exercise, changes in daily activities, physiotherapy, nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics .However ,the intra-articular injection is recently recommended by many studies such as corticosteroids, hyaluronic acid, Growth hormone, dextrose ,and platelet rich plasma.

Intra-articular injection of platelets are activated and undergo degranulation, releasing a range of growth factors, including transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF), insulin-like growth factor, vascular endothelial growth factors, epidermal growth factors and basic fibroblast growth factor 2. These growth factors are thought to activate a variety of signaling pathways, which promote healing of bone and soft tissue.Also,some minimally invasive therapeutic options have been effective in pain relieve in KA, such as ultrasound-guided saphenous nerve block .

Detailed Description

The aim of this study is to compare the efficacy of ultrasound guided saphenous nerve block versus platelet rich plasma injection in the management of chronic pain in patients with knee OA. This study will be conducted to evaluate which modality is more effective.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
56
Inclusion Criteria
  • Patients who are not competent to understand the study protocol
  • Radiographic evidence of OA of knee of 2nd degree.
  • Chronic pain for at least 6 months prior to study entry (day 0).
  • Pain relief not achieved with conservative therapies during the last 6 months
Exclusion Criteria
  • Patient refusal.
  • Bleeding disorders.
  • Coagulation disorders.
  • Local skin infection
  • Current other problem in the affected extremity .
  • Psychiatric disorders affecting co-operation of the patient .
  • Previous chronic opioid use.
  • Intra articular knee injection within previous three months.
  • History of traumatic arthropathy.
  • History of neuropathic arthropathy.
  • Allergy or hypersensitivity to any of the study medication.
  • Any condition that could interfere with the interpretation of the outcome assessments.
  • Pregnancy
  • Lactating women.
  • low back pain due to central cause.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Saphenous nerve block groupSaphenous nerve block groupPatients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
Platelet rich plasma groupPlatelet rich plasma groupPatients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
Primary Outcome Measures
NameTimeMethod
Pain scoresFor 6 months after intervention

The severity of pain will be assessed using a visual analog scale (VAS)

Secondary Outcome Measures
NameTimeMethod
Quality of life (QOL)For 6 months after intervention

is evaluated using the Western Ontario and MC Master universities (WOMAC) index of osteoarthritis

Trial Locations

Locations (1)

Mansoura University Hospitals

🇪🇬

Mansourah, DK, Egypt

© Copyright 2025. All Rights Reserved by MedPath